JP2020516668A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020516668A5 JP2020516668A5 JP2019556226A JP2019556226A JP2020516668A5 JP 2020516668 A5 JP2020516668 A5 JP 2020516668A5 JP 2019556226 A JP2019556226 A JP 2019556226A JP 2019556226 A JP2019556226 A JP 2019556226A JP 2020516668 A5 JP2020516668 A5 JP 2020516668A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- cancer
- amhrii
- binding agent
- agent according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305445 | 2017-04-14 | ||
| EP17305445.3 | 2017-04-14 | ||
| PCT/EP2018/059548 WO2018189379A1 (en) | 2017-04-14 | 2018-04-13 | Amhrii-binding compounds for preventing or treating cancers |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020516668A JP2020516668A (ja) | 2020-06-11 |
| JP2020516668A5 true JP2020516668A5 (enExample) | 2021-05-20 |
Family
ID=58672545
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019556226A Pending JP2020516668A (ja) | 2017-04-14 | 2018-04-13 | 癌を予防又は処置する為のａｍｈｒｉｉ結合性化合物 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20190367625A1 (enExample) |
| EP (1) | EP3609918A1 (enExample) |
| JP (1) | JP2020516668A (enExample) |
| KR (1) | KR20200014276A (enExample) |
| CN (2) | CN110891970B (enExample) |
| BR (1) | BR112019021472A8 (enExample) |
| CA (1) | CA3058282A1 (enExample) |
| MX (1) | MX2019012137A (enExample) |
| WO (1) | WO2018189379A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2019012136A (es) * | 2017-04-14 | 2020-07-20 | Gamamabs Pharma | Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon. |
| WO2020214563A1 (en) * | 2019-04-15 | 2020-10-22 | The Trustees Of The University Of Pennsylvania | Müllerian inhibiting substance type 2 receptor (misiir)-specific car t cells for the treatment of ovarian cancer and other gynecologic malignancies |
| WO2020243679A1 (en) * | 2019-05-31 | 2020-12-03 | Detti Laura | Anti-mullerian hormone receptor binding peptides |
| EP3789401A1 (en) * | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
| EP3812008A1 (en) * | 2019-10-23 | 2021-04-28 | Gamamabs Pharma | Amh-competitive antagonist antibody |
| WO2021155295A1 (en) * | 2020-01-31 | 2021-08-05 | The Cleveland Clinic Foundation | Anti-müllerian hormone receptor 2 antibodies and methods of use |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| ES2113940T3 (es) | 1990-12-03 | 1998-05-16 | Genentech Inc | Metodo de enriquecimiento para variantes de proteinas con propiedades de union alteradas. |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| US5565332A (en) | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
| DE69233528T2 (de) | 1991-11-25 | 2006-03-16 | Enzon, Inc. | Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| CA2194907A1 (en) | 1994-07-13 | 1996-02-01 | Kouji Matsushima | Reshaped human antibody against human interleukin-8 |
| IL138608A0 (en) | 1998-04-02 | 2001-10-31 | Genentech Inc | Antibody variants and fragments thereof |
| US6528624B1 (en) | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
| US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
| US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
| KR100940380B1 (ko) | 1999-01-15 | 2010-02-02 | 제넨테크, 인크. | 효과기 기능이 변화된 폴리펩티드 변이체 |
| WO2005005615A2 (en) * | 2003-07-08 | 2005-01-20 | Fox Chase Cancer Center | Anti-mullerian inhibiting substance type ii receptor (misiir) immunoconjugates to detect and treat cancer |
| EP1918304A1 (en) | 2006-11-02 | 2008-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Monoclonal antibodies against the human anti-müllerian hormone type II receptor (AMHR-II) |
| FR2959994B1 (fr) * | 2010-05-12 | 2012-08-24 | Lfb Biotechnologies | Nouveaux anticorps humanises 12g4 mutes et leurs fragments diriges contre le recepteur humain de l'hormone anti-mullerienne de type ii |
| FR2984750B1 (fr) * | 2011-12-23 | 2014-01-10 | Lfb Biotechnologies | Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii |
| EP3046582A4 (en) * | 2013-09-20 | 2017-05-10 | The General Hospital Corporation | Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases |
| US20160250190A1 (en) * | 2013-10-18 | 2016-09-01 | The General Hospital Corporation | N-methyl pyrazoloanthrone for treatment of cancer |
| EP3331569A1 (en) * | 2015-08-07 | 2018-06-13 | Gamamabs Pharma | Antibodies, antibody drug conjugates and methods of use |
| WO2017040969A1 (en) * | 2015-09-02 | 2017-03-09 | The Cleveland Clinic Foundation | Ovarian cancer vaccines |
| MX2019012136A (es) * | 2017-04-14 | 2020-07-20 | Gamamabs Pharma | Compuestos de union al receptor de la hormona antimulleriana tipo ii (amhrii) para prevenir o tratar canceres de pulmon. |
| EP3789401A1 (en) * | 2019-09-03 | 2021-03-10 | Gamamabs Pharma | Amhrii-binding antibody drug conjugates and their use thereof in the treatment of cancers |
-
2018
- 2018-04-13 CA CA3058282A patent/CA3058282A1/en active Pending
- 2018-04-13 MX MX2019012137A patent/MX2019012137A/es unknown
- 2018-04-13 CN CN201880040178.5A patent/CN110891970B/zh not_active Expired - Fee Related
- 2018-04-13 JP JP2019556226A patent/JP2020516668A/ja active Pending
- 2018-04-13 KR KR1020197033359A patent/KR20200014276A/ko not_active Ceased
- 2018-04-13 EP EP18718419.7A patent/EP3609918A1/en not_active Withdrawn
- 2018-04-13 BR BR112019021472A patent/BR112019021472A8/pt unknown
- 2018-04-13 WO PCT/EP2018/059548 patent/WO2018189379A1/en not_active Ceased
- 2018-04-13 CN CN202410572835.8A patent/CN118453852A/zh active Pending
-
2019
- 2019-06-07 US US16/434,232 patent/US20190367625A1/en not_active Abandoned
-
2021
- 2021-11-24 US US17/535,004 patent/US20220144959A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Liu et al. | Targeting alpha-fetoprotein (AFP)–MHC complex with CAR T-cell therapy for liver cancer | |
| JP2009505676A5 (enExample) | ||
| JP2017515792A5 (enExample) | ||
| JP2020063262A5 (enExample) | ||
| JP2020511936A5 (enExample) | ||
| FI3833386T3 (fi) | Monispesifisiä sitoutuvia proteiineja, jotka sitovat her2:ta, nkg2d:tä ja cd16:ta, ja käyttömenetelmiä | |
| JP2020500523A5 (enExample) | ||
| JP2018530331A5 (enExample) | ||
| JP2015529641A5 (enExample) | ||
| US20170129967A1 (en) | Car-expressing nk-92 cells as cell therapeutic agents | |
| JP2020516305A5 (enExample) | ||
| FI3515487T3 (fi) | Bispesifisiä anti-MUC16-CD3-vasta-aineita ja anti-MUC16-lääkekonjugaatteja | |
| Giles et al. | Efficient ADCC killing of meningioma by avelumab and a high-affinity natural killer cell line, haNK | |
| HRP20180507T1 (hr) | Identifikacija antigena povezanih s tumorom za dijagnozu i terapiju | |
| JP2019507135A5 (enExample) | ||
| JOP20190248A1 (ar) | بروتينات ربط مولد ضد trem2 واستخداماته | |
| JPWO2019189780A5 (enExample) | ||
| JP2020516655A5 (enExample) | ||
| JP2013527761A5 (enExample) | ||
| JP2017526632A5 (enExample) | ||
| JP2022513586A5 (enExample) | ||
| JP2014518615A5 (enExample) | ||
| HRP20180262T1 (hr) | Monoklonska anti-gt468 protutijela za liječenje karcinoma | |
| JP2017507936A5 (enExample) | ||
| JP2016513458A5 (enExample) |